Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAli T. Taheren_US
dc.contributor.authorJohn B. Porteren_US
dc.contributor.authorVip Viprakasiten_US
dc.contributor.authorAntonis Kattamisen_US
dc.contributor.authorSuporn Chuncharuneeen_US
dc.contributor.authorPranee Sutcharitchanen_US
dc.contributor.authorNoppadol Siritanaratkulen_US
dc.contributor.authorRenzo Galanelloen_US
dc.contributor.authorZeynep Karakasen_US
dc.contributor.authorTomasz Lawniczeken_US
dc.contributor.authorDany Habren_US
dc.contributor.authorJacqueline Rosen_US
dc.contributor.authorZewen Zhuen_US
dc.contributor.authorM. Domenica Cappellinien_US
dc.contributor.otherAmerican University of Beiruten_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Athensen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherUniversita degli Studi di Cagliarien_US
dc.contributor.otherIstanbul Tip Fakultesien_US
dc.contributor.otherNovartis International AGen_US
dc.contributor.otherNovartis Pharmaceuticalsen_US
dc.contributor.otherUniversita degli Studi di Milanoen_US
dc.identifier.citationAnnals of Hematology. Vol.92, No.11 (2013), 1485-1493en_US
dc.description.abstractPatients with non-transfusion-dependent thalassemia (NTDT) often develop iron overload that requires chelation to levels below the threshold associated with complications. This can take several years in patients with high iron burden, highlighting the value of long-term chelation data. Here, we report the 1-year extension of the THALASSA trial assessing deferasirox in NTDT; patients continued with deferasirox or crossed from placebo to deferasirox. Of 133 patients entering extension, 130 completed. Liver iron concentration (LIC) continued to decrease with deferasirox over 2 years; mean change was -7.14 mg Fe/g dry weight (dw) (mean dose 9.8 ± 3.6 mg/kg/day). In patients originally randomized to placebo, whose LIC had increased by the end of the core study, LIC decreased in the extension with deferasirox with a mean change of -6.66 mg Fe/g dw (baseline to month 24; mean dose in extension 13.7 ± 4.6 mg/kg/day). Of 166 patients enrolled, 64 (38.6 %) and 24 (14.5 %) patients achieved LIC <5 and <3 mg Fe/g dw by the end of the study, respectively. Mean LIC reduction was greatest in patients with the highest pretreatment LIC. Deferasirox progressively decreases iron overload over 2 years in NTDT patients with both low and high LIC. Safety profile of deferasirox over 2 years was consistent with that in the core study. © 2013 The Author(s).en_US
dc.rightsMahidol Universityen_US
dc.titleDeferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.